VeronikaBachanovaMDPhD

Hematologic Oncology

Professor of Medicine, University of Minnesota Medical School, Section Head for Malignant Hematology, Director of Hematologic Malignancies Tissue Bank

Join to view full profile

Dr. Bachanova is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bachanova's full profile

Already have an account?

Office
516 Delaware St SE Ste 5100
University OT Minnesota Physicians
Minneapolis, MN 55455
Phone+1 612-626-2663

Summary

I am a board certified hematologist/oncologist specializing in bone marrow transplantation, cellular therapies and immunotherapies to treat lymphoma and leukemia. My mission to make new promising therapies available to all patients and offer compassionate care at the highest standards. I lead CAR-T program at University of Minnesota.

Education & Training

University of MinnesotaFellowship, Hematology and Medical Oncology, 2004 - 2007
Henry Ford Health/Henry Ford HospitalResidency, Internal Medicine, 1995 - 1998
Comenius UniversityClass of 1992

Certifications & Licensure

MN State Medical License 2006 - 2024
TX State Medical License 1998 - 2005
MI State Medical License 1998 - 1999

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma Start of enrollment: 2005 Aug 24
Completed
Phase 2
Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia Start of enrollment: 2008 Jan 01
Terminated
Phase 1, Phase 2
Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701) Start of enrollment: 2009 Apr 01
Completed
Phase 2
A Phase I Study of GNKG168 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) Start of enrollment: 2009 Sep 01
Terminated
Phase 1
Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies Start of enrollment: 2010 Aug 01
Completed
Phase 2
A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHL Start of enrollment: 2013 Nov 25
Terminated
Phase 1, Phase 2
ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL Start of enrollment: 2014 May 01
Completed
Phase 1, Phase 2
Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHL Start of enrollment: 2014 Nov 04
Terminated
Phase 1, Phase 2
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL Start of enrollment: 2017 Oct 18
Completed
Phase 1
Auto Stem Cell Transplant for Lymphoma Patients Start of enrollment: 2017 Apr 20
Recruiting
Phase 2
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma Start of enrollment: 2018 Sep 13
Recruiting
Phase 1, Phase 2
Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL Start of enrollment: 2024 Sep 01
Not yet recruiting
Phase 1, Phase 2
Roles: Contact
Evaluation of Early Identification of Cognitive Side Effects of Immunotherapy Start of enrollment: 2024 Feb 08
Recruiting
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

2298 citations
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster, Michael R. Bishop, Constantine S. Tam, Edmund K. Waller, Peter Borchmann
The New England Journal of Medicine. 2019-01-03
106 citations
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study.
Jeremy S Abramson, Scott R Solomon, Jon Arnason, Patrick B Johnston, Bertram Glass
Blood. 2023-04-06
212 citations
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with r...
Manali Kamdar, Scott R Solomon, Jon Arnason, Patrick B Johnston, Bertram Glass
Lancet. 2022-06-18

Journal Articles

Diffuse Alveolar Hemorrhage Is Most Often Fatal and Is Affected by Graft Source, Conditioning Regiment Toxicity, and Engraftment Kinetics
Erhan H Dincer, Erica D Warlick, Margaret L MacMillan, Patrick Arndt, Daniel J Weisdorf, Nelli Bejanyan, Claudio G Brunstein, Celalettin Ustun, Aleksandr Lazaryan, Ver..., Haematologica
Five-Year PFS from the AETHERA Trial of Brentuximab Vedotin for Hodgkin Lymphoma at High Risk of Progression or Relapse
Patrick Stiff, Edward Agura, Craig H Moskowitz, John Sweetenham, Auayporn Nademanee, Veronika Bachanova, Blood

Abstracts/Posters

Outcomes of Chronic Graft-Versus-Host Disease (cGVHD) Following Matched Sibling Donor (MSD) Versus Umbilical Cord Blood Transplant (UCBT)
Veronika Bachanova, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
Veronika Bachanova, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma
Veronika Bachanova, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecl...
Veronika Bachanova, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
Veronika Bachanova, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Preliminary Clinical Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20+ non-Hodgkin Lymphoma
Veronika Bachanova, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagen...
Veronika Bachanova, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pat...
Veronika Bachanova, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant
Veronika Bachanova, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies: Results of phase I-II trial.
2019 ASCO Annual Meeting - 6/1/2019
Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial o...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Advancement in Research Improves Checkpoint Inhibitor Therapy for CancerJune 27th, 2024
Immunosuppressant Ruxolitinib Boosts Checkpoint Inhibitor Response in Patients with Hodgkin Lymphoma, Phase I Data ShowJune 20th, 2024
Clinical Challenges: Managing Hodgkin's in PregnancyDecember 18th, 2020
Join now to see all